Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 3:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 17,839 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy Participants
Interventions
Abiraterone acetate, 250 mg (uncoated, current commercial tablet), Abiraterone acetate, 500 mg (coated, reformulated tablet), Abiraterone acetate, 250 mg (coated, reformulated tablet), Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Small Cell Lung Cancer
Interventions
SC-002
Drug
Lead sponsor
Stemcentrx
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 1 more
Conditions
Amyloidosis
Interventions
Bortezomib, Dexamethasone, Melphalan
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
61
States / cities
Little Rock, Arkansas • Carson, California • Cerritos, California + 58 more
Conditions
Heart Failure, Decompensated Heart Failure, Acute Heart Failure
Interventions
CXL-1427, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Gainesville, Florida • Jacksonville, Florida • Macon, Georgia + 10 more
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 3 Days
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Conditions
Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach
Interventions
Vandetanib, 5 Fluorouracil (FU), Carboplatin, Paclitaxel, External Beam Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Acute Myeloid Leukemia
Interventions
ASTX660, ASTX727
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 11 more
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Male Breast Cancer, Mixed Adenocarcinoma of the Stomach, Ovarian Endometrioid Adenocarcinoma, Paget Disease of the Breast With Intraductal Carcinoma, Paget Disease of the Breast With Invasive Ductal Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Salivary Gland Adenocarcinoma, Stage II Malignant Testicular Germ Cell Tumor, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Gallbladder Cancer
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Healthy or Stable Chronic Illness
Interventions
Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
2,312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
110
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 95 more
Enrolling by invitation Early Phase 1 Interventional

Truway Diagnostic Tools in Primary Care

NCT07209527
Conditions
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions
Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Transplant; Failure, Kidney
Interventions
Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids
Drug
Lead sponsor
Gaetano Ciancio
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Conditions
Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer
Interventions
AsiDNA, Olaparib
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Tetanus, Acellular Pertussis, Diphtheria
Interventions
SB213503 lot 1, SB213503 lot 2, SB213503 lot 3, Infanrix, IPOL, M-M-R II
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
4,209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
24
States / cities
Little Rock, Arkansas • Antioch, California • Daly City, California + 20 more
Conditions
Triple Negative Breast Neoplasms
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
39
States / cities
Mobile, Alabama • Chandler, Arizona • Duarte, California + 33 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
benzoylphenylurea, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Interventions
TAA-T cells, Nivolumab
Biological · Drug
Lead sponsor
Catherine Bollard
Other
Eligibility
12 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

NCT03950856
Conditions
Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
V114, Prevnar 13™
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
2,340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
30
States / cities
Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more
Conditions
Lung Adenocarcinoma
Interventions
erlotinib with cetuximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pancreatitis, Hyperalgesia, Opioid Use Disorder, Opioid-Related Disorders, Opioid Dependence, Chronic Abdominal Pain, ERCP, Pancreatic Surgery
Interventions
Lacosamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Stanford, California • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Conditions
Healthy Volunteers, Psoriasis
Interventions
PBI-100 Topical Cream, Vehicle Cream
Drug
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Conditions
Achondroplasia
Interventions
Recifercept
Biological
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 10 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Aliso Viejo, California • Irvine, California • Long Beach, California + 3 more
Conditions
Infertility
Interventions
Follitropin delta, Placebo
Drug · Other
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Tempe, Arizona • Encino, California • Farmington, Connecticut + 20 more
Conditions
Sickle Cell Disease
Interventions
Briquilimab, Filgrastim, Abatacept, Sirolimus, Cyclophosphamide
Biological · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland